ES2075005T5 - G-csf humano modificado. - Google Patents

G-csf humano modificado.

Info

Publication number
ES2075005T5
ES2075005T5 ES89105728T ES89105728T ES2075005T5 ES 2075005 T5 ES2075005 T5 ES 2075005T5 ES 89105728 T ES89105728 T ES 89105728T ES 89105728 T ES89105728 T ES 89105728T ES 2075005 T5 ES2075005 T5 ES 2075005T5
Authority
ES
Spain
Prior art keywords
csf
variable positive
optionally variable
group
positive integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89105728T
Other languages
English (en)
Other versions
ES2075005T3 (es
Inventor
Motoo Yamasaki
Yoshiharu Yokoo
Makoto Morimoto
Masami Okabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13708444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2075005(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2075005T3 publication Critical patent/ES2075005T3/es
Publication of ES2075005T5 publication Critical patent/ES2075005T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN POLIPEPTICO MODIFICADO QUE PRESENTA ACTIVIDAD DE FACTOR ESTIMULANTE DE LA COLONIA GRANULOCITICA HUMANA (HG - CSF) COMPRENDE UN POLIPEPTIDO QUE TIENE ACTIVIDAD HG - CSF CON AL MENOS UN GRUPO AMINO SUSTITUIDO CON UN GRUPO QUE RESPONDE A LA FORMULA (FORMULA I): DONDE R1 ES UN GRUPO ALQUILO O ALCANOILO, N ES UN NUMERO ENTERO POSITIVO QUE PUEDE VARIAR OPCIONALMENTE; X ES 0, NH O S; R2 ES (FORMULA II): (DONDE R3 ES - OH, CL, O - (CH2CH2O)N - R1, DONDE R1 Y N RESPONDEN A LA DEFINICION ANTERIOR, Y PUEDE SER Z - (CH2)PCO, DONDE Z ES O, S O NH Y P ES UN ENTERO POSITIVO VARIABLE OPCIONALMENTE, O NO ESTAR PRESENTE), O (CO)M - (CH2)L CO, DONDE M ES 0 O 1, L ES UN ENTERO POSITIVO VARIABLE OPCIONALMENTE, QUE PUEDE CONTRIBUIR CON UN MAYOR EFECTO DE AUMENTO EN LOS LEUCOCITOS PERIFERICOS (GRANULOCITOS) CON MAYOR ESTABILIDAD Y TIEMPO DE PERMANENCIA EN LA SANGRE Y, COMO TAL, PUEDE UTILIZARSE VENTAJOSAMENTE EN MEDICINA CLINICA.
ES89105728T 1988-03-31 1989-03-31 G-csf humano modificado. Expired - Lifetime ES2075005T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8008888 1988-03-31

Publications (2)

Publication Number Publication Date
ES2075005T3 ES2075005T3 (es) 1995-10-01
ES2075005T5 true ES2075005T5 (es) 2003-11-01

Family

ID=13708444

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89105728T Expired - Lifetime ES2075005T5 (es) 1988-03-31 1989-03-31 G-csf humano modificado.

Country Status (10)

Country Link
EP (1) EP0335423B2 (es)
AT (1) ATE126235T1 (es)
AU (2) AU620385B2 (es)
CA (1) CA1340810C (es)
DE (1) DE68923723T3 (es)
ES (1) ES2075005T5 (es)
GR (1) GR3017188T3 (es)
HK (1) HK59396A (es)
HU (2) HU211958A9 (es)
LV (1) LV11692B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5885570A (en) * 1991-01-23 1999-03-23 The General Hospital Corporation Induction of tolerance with modified immunogens
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JP4011106B2 (ja) * 1994-02-23 2007-11-21 協和醗酵工業株式会社 血小板増殖促進剤
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
CN1058292C (zh) * 1995-02-16 2000-11-08 中国人民解放军军事医学科学院基础医学研究所 一种制造重组人粒－巨噬细胞集落刺激因子的方法
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
JP4011124B2 (ja) 1997-06-06 2007-11-21 協和醗酵工業株式会社 化学修飾ポリペプチド
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
KR100508358B1 (ko) 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
JP5225393B2 (ja) 2008-02-18 2013-07-03 ジエンス ヘンルイ メデイシンカンパニー リミテッド 水溶性高分子修飾ｇ−ｃｓｆ複合体
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
EP2542574B1 (en) 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
EP2900821B1 (en) 2012-09-25 2020-04-01 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol

Also Published As

Publication number Publication date
CA1340810C (en) 1999-11-02
DE68923723D1 (de) 1995-09-14
AU620385B2 (en) 1992-02-20
EP0335423A2 (en) 1989-10-04
HK59396A (en) 1996-04-12
GR3017188T3 (en) 1995-11-30
HU211935A9 (en) 1996-01-29
DE68923723T3 (de) 2003-12-18
LV11692B (en) 1997-08-20
AU640567B2 (en) 1993-08-26
AU1703292A (en) 1992-07-16
HU211958A9 (en) 1996-01-29
LV11692A (lv) 1997-02-20
ES2075005T3 (es) 1995-10-01
EP0335423B1 (en) 1995-08-09
DE68923723T2 (de) 1996-02-15
ATE126235T1 (de) 1995-08-15
EP0335423A3 (en) 1991-07-03
AU3234189A (en) 1989-10-05
EP0335423B2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
DE68923723D1 (de) Modifizierter humaner G-CSF.
FR2421888A1 (fr) Amides d'alkylene-diamines et leur application en therapeutique
FR2417500A1 (fr) Derives d'amino-acides cycliques dehydrogenes et leur utilisation therapeutique
FR2603037B1 (fr) (pentamethyl-1,2,2,6,6,6 piperidyl-4 amino)- triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent
FI912144A7 (fi) Somatotropiinien ja muiden proteiinien stabilointi muuntamalla kysteiiniryhmiä
FR2523962B1 (fr) Nouveaux amides d'acides aldoniques, leur preparation et compositions les contenant
DK176285D0 (da) Fremstilling af polypeptider med human-gamma-interferonaktivitet
SE8404065D0 (sv) Novel biologically active compounds
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
ATE213950T1 (de) Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen
IT8419046A1 (it) Composizioni vulcanizzabili di fluoroelastomeri aventi migliorate caratteristiche di autolubrificazione ed elevata velocita' di vulcanizzazione
ATE1856T1 (de) Peptide mit ubiquitin-aehnlicher aktivitaet, verfahren zu ihrer herstellung, sie enthaltende therapeutische zusammensetzungen und ihrer anwendung.
DK12990D0 (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
GR3015052T3 (en) Antibiotic GE 2270 factors A1, A2, A3 and H.
ES2001697A6 (es) Procedimiento para preparar 2-aminopurinas sustituidas en posiciones 6 y 9
FR2631339B1 (fr) Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
GR3015899T3 (en) Antibiotic GE 2270 factors B1, B2, C1, C2, D1, D2,E and T.
DE69118064D1 (de) Diamino-s-Triazinonderivate und diese enthaltende selbstlöschende polymere Zusammensetzungen
DE69018275D1 (de) Peptide, deren Verwendung als Hemmer gegen Entwicklung von t-Lymphocyten und Wirksamkeit von Makrophagen und Verfahren zu deren Herstellung.
IL84551A0 (en) Peptides,their preparation and pharmaceutical compositions containing them
FI911219A0 (fi) Ny pentapeptid och foerfarande foer framstaellning av densamma.
DE69009211D1 (de) Derivate von Thiazolidin-4-carbonsäure, deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE3880304D1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
ATE55123T1 (de) Alkylcarbonsaeureamide von pyridinalkylaminen, ihre herstellung und ihre verwendung als arzneimittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 335423

Country of ref document: ES